Author(s): Guillermo Montalban-Bravo, Prithviraj Bose, Yesid Alvarado, et. al. Abstract: P 315 Session topic: 10. Myelodysplastic syndromes – Clinical Background: Improving the current response and survival outcomes of patients with higher risk MDS and CMML is fundamental. Guadecitabine is a next generation hypomethylating agent with increased length of exposure compared to decitabine...
Pro zobrazení tohoto obsahu je třeba být přihlášen.